

REMARKS

The Applicants file this Amendment and RCE to claim the scope defined above for the invention.

Claims 1-20 are canceled.

Claims 21- 35 are new.

Support for the new claims may be found in the Specification and previous claims. Added support for new claims 21 – 25 may be found in the Specification on page 1 in the penultimate paragraph.


Applicants respectfully request entry of this amendment and favorable consideration of the claims in light thereof.

The Examiner is authorized to charge any fees which may be due under 37 C.F.R. 1.17 or credit any overpayment to Account No. 19-0134 in the name of Novartis Corporation.

If it will advance prosecution of this matter the Examiner is encouraged to contact the Applicants' undersigned counsel at the phone number listed below.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7960

  
Edward J. Wilusz, Jr.  
Attorney for Applicant  
Reg. No. 52,370

Date: 14 June 2005